|
1）Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature Committee of the International Society of Amyloidosis. Amyloid. 2012; 19: 167-70
|
|
|
|
2）Arima T, Ando Y, Ando E, et al. Secondary amyloidosis with severe autonomic dysfunctions. J Auton Nerv Syst. 1995; 52: 77-81
|
|
|
|
|
|
3）Ando Y, Suhr OB. Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid. 1998; 5: 288-300
|
|
|
|
|
|
4）Valleix S, Gillmore JD, Bridoux F, et al. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med. 2012; 366: 2276-83
|
|
|
|
|
|
5）Ando Y, Nakamura M, Araki S. Transthyretin related familial amyloidotic polyneuropathy. Arch Neurol. 2005; 62: 1057-62
|
|
|
|
|
|
6）Misu K, Hattori N, Nagamatsu M, et al. Late-onset familial amyloiudotic polyneuropathy type I (Met30 transthyretin mutation) unrelated to endemic focus in Japan: Clinicopathologic and genetic features. Brain. 1999; 122: 1951-62
|
|
|
|
|
|
7）Ikeda S, Nakazato M, Ando Y, et al. Familial amyloidotic polyneruoapthy in Japan: Clinical and genetic heterogeneity. Neurology. 2002; 58: 1001-7
|
|
|
|
|
|
8）Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 1186: 1750-72
|
|
|
|
|
|
9）Ando Y, Yonehara T, Tanaka Y, et al. Early pacemaker implantation in patients with familial amyloidotic polyneuropathy. Muscle Nerve. 1996; 19: 1640-1
|
|
|
|
|
|
10）Yonehara T, Ando Y, Kimura K, et al. Detection of reverse flow by duplex ultrasonography in orthostatic hypotension. Stroke. 1994; 25: 2407-11
|
|
|
|
|
|
11）Ando Y, Obayashi K, Tanaka Y, et al. Radiolabelled meta-iodobenzylguanidine in assessment of autonomic dysfunction. Lancet. 1994; 343: 984-5
|
|
|
|
|
|
12）Ando E, Ando Y, Okamura R, et al. Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up. Br J Ophthalmol. 1997; 81: 295-8
|
|
|
|
|
|
13）Ando E, Ando Y, Maruoka S, et al. Ocular microangiopathy in familial amyloidotic polyneuropathy, type I. Graefee Arch Clin Exp Ophthalmol. 1992; 230: 1-5
|
|
|
|
|
|
14）Ando Y, Yi S, Nakagawa T, et al. Disturbed metabolism of glucose and related hormones in familial amyloidotic polyneuropathy. J Auton Nerv Syst. 1991; 35: 63-70
|
|
|
|
|
|
15）Obayashi K, Ando Y, Terazaki H, et al. Effect of sildenafil citrate (Viagra) on erectile dysfunction in a patient with familial amyloidotic polyneuropathy ATTR Val30Met. J Auton Nerv Syst. 2000; 80: 89-92
|
|
|
|
|
|
16）Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012; 78: 637-43
|
|
|
|
|
|
17）Ando E, Ando Y, Haraoka K. Ocular amyloid imvolvement after liver transplantation for polyneuropathy. Ann Intern Med. 2001; 135: 931-2
|
|
|
|
|
|
18）Stangou AJ, Hawkins PN, Heaton ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998; 66: 229-33
|
|
|
|
|
|
19）Obayashi K, Yamashita T, Tasaki M, et al. Amyloid neuropathy in a younger domino liver transplanted recipient. Muscle Nerve. 2011; 43: 449-50
|
|
|
|
|
|
20）Berk JL, Suhr OB, Obici L, et al. Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013; 10: 2658-67
|
|
|
|
|